

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Nicholas Hannebery
Date of last notice	7 April 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect (1) Shares held by Robyn Gould (spouse of Richard Hannebery) Indirect (2) EG Capital Pty Limited, an entity in which Richard Hannebery has an interest Indirect (3) Silica Investments Pty Ltd, an entity in which Richard Hannebery has an interest
Date of change	7 April 2017

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct</u> 293,202 fully paid ordinary shares 1,000,000 performance rights vesting 31/12/17 subject to milestones</p> <p><u>Indirect (1)</u> 4,405,000 fully paid ordinary shares</p> <p><u>Indirect (2)</u> 948,228 fully paid ordinary shares</p> <p><u>Indirect (3)</u> 1,014,083 fully paid ordinary shares 2,500,000 options exercisable at \$0.15 expiry 2/12/17</p>
Class	Ordinary Shares
Number acquired	22,947
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$4,130
No. of securities held after change	<p><u>Direct</u> 316,149 fully paid ordinary shares 1,000,000 performance rights vesting 31/12/17 subject to milestones</p> <p><u>Indirect (1)</u> 4,405,000 fully paid ordinary shares</p> <p><u>Indirect (2)</u> 948,228 fully paid ordinary shares</p> <p><u>Indirect (3)</u> 1,014,083 fully paid ordinary shares 2,500,000 options exercisable at \$0.15 expiry 2/12/17</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	7 April 2017

⁺ See chapter 19 for defined terms.